Key terms
About LQDA
Liquidia Corp. operates as a holding company which through its subsidiary engages in developing and commercializing biopharmaceutical products. It engages in novel products development used in PRINT technology to transform the lives of patients. The company was founded on June 28, 2020, and is headquartered in Morrisville, NC.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest LQDA news
Apr 02
5:11am ET
Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT), Liquidia Technologies (LQDA) and Xtant Medical Holdings (XTNT)
Apr 01
10:35am ET
Buy Rating Justified by Favorable Legal Outcomes and Imminent FDA Decision for Liquidia Technologies’ Yutrepia
Apr 01
6:11am ET
Liquidia provides YUTREPIA regulatory update
Mar 15
11:32am ET
Biotech Alert: Searches spiking for these stocks today
Mar 14
10:25am ET
Liquidia Technologies Faces Sell Rating Amid Legal Struggles and Market Competition
Mar 14
6:26am ET
Buy Rating Affirmed for Liquidia Technologies with Doubling Price Target on Yutrepia’s Promising Prospects
Mar 14
6:10am ET
Analysts Offer Insights on Healthcare Companies: Liquidia Technologies (LQDA) and Legend Biotech (LEGN)
Mar 14
5:47am ET
Strong Growth Prospects for Liquidia Technologies with Impending Approvals and Robust Product Pipeline
Mar 13
2:55pm ET
Buy Rating Affirmed for Liquidia Technologies Amid Favorable Legal Rulings and Yutrepia’s Market Potential
Feb 21
1:15pm ET
Buy Rating Affirmed for Liquidia Technologies Amidst Strong Market Growth and Favorable Regulatory Outlook
Feb 21
6:07am ET
United Therapeutics commences litigation with FDA on drug review process
Feb 12
4:36am ET
United Therapeutics upgraded to Neutral from Sell at Goldman Sachs
Feb 07
12:05pm ET
Liquidia Technologies call volume above normal and directionally bullish
Jan 26
4:06am ET
Liquidia Technologies Announces YUTREPIA Application Update
Jan 25
11:05am ET
Maintaining Buy Rating on Liquidia Technologies Amid FDA Delay: A Procedural Hiccup, Not a Setback
Jan 25
10:18am ET
Sell Rating on Liquidia Technologies Amid Regulatory Delays and Patent Litigation
Jan 25
9:25am ET
Buy Rating Upheld for Liquidia Technologies Amid Strong Market Prospects for YUTREPIA
Jan 25
9:11am ET
Liquidia update does not reflect new patent stay, says BTIG
Jan 25
6:04am ET
Liquidia provides update on NDA for YUTREPIA
Jan 24
3:06am ET
Liquidia Technologies Sees Patent Claims Dismissed by United Therapeutics
Jan 23
11:55am ET
Liquidia Technologies put volume heavy and directionally bearish
Jan 20
3:02am ET
Liquidia Technologies Announces New Chief Operating Officer
Jan 19
6:35am ET
Liquidia appoints CFO Michael Kaseta as COO
Jan 17
12:45pm ET
Liquidia Technologies call volume above normal and directionally bullish
Jan 08
8:31am ET
Liquidia files response and counterclaims to United Therapeutics lawsuit
Jan 07
5:39am ET
BTIG Remains a Buy on Liquidia Technologies (LQDA)
Jan 05
7:35am ET
Liquidia added to Conviction Buy, named 2024 Top Pick at Needham
Jan 05
6:49am ET
Liquidia provides update on clinical pipeline targeting PAH and PH-ILD
Jan 05
6:35am ET
Buy Rating Affirmed for Liquidia Technologies Post-Court Win and Strong Financial Position
Jan 04
9:20am ET
Liquidia announces $100M in new financings
Jan 03
8:45am ET
Largest borrow rate increases among liquid names
No recent press releases are available for LQDA
LQDA Financials
Key terms
Ad Feedback
LQDA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
LQDA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
